Table 1.

Patient characteristics

Characteristic	Overall population (N = 1386)	Patients who discontinued ibrutinib therapy (N = 247)
Age, median years (min–max)	72 (23–96)c	77 (42–95)d
Age ≥ 65, n (%)	1082 (78.1)c	221 (89.5)d
Age ≥ 75, n (%)	560 (40.4)c	145 (58.7)d
Sex, n (%)
Male	1033 (74.5)	183 (74.1)
Female	353 (25.5)	64 (25.9)
Bone marrow involvement, n (%)	79 (5.7)e	15 (6.1)f
CCI, mean (SD)	2.2 (1.4)e	2.8 (1.6)f
BMI, mean (SD)a	22.6 (3.4)e	22.3 (3.7)f
Total ADL independence, n (%)b
Independent	1015 (87.0)e	69 (61.1)f
Dependent	152 (13.0)e	44 (38.9)f

^aResults were available only from discharge summaries for 1211 patients in the overall population and 119 post-ibrutinib therapy patients

^bResults were available only from discharge summaries for 1167 patients in the overall population and 113 post-ibrutinib therapy patients

^cEvaluated at index date

^dEvaluated at the end of ibrutinib therapy

^eEvaluated at baseline before 1L

^fEvaluated during ibrutinib therapy

ADL activities of daily living, BMI body mass index, CCI Charlson Comorbidity Index, SD standard deviation